Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_3720_Библиотеки_им_академика_М_И_Перельмана
.pdf
140 Cardiovascular Thrombus
https://t.me/med1917
(A) (C)(B)
DES
1.4mm ELCA
(E) (F)(D)
Filterwire EZ
FIGURE 9.7 Use of laser as a thrombus debulking mechanism. (A) Angiogram pre-PCI (arrow shows thrombus). (B) ELCA laser in use (arrow). (C)
Postlaser angiogram (star shows reduction in thrombus size). (D) Drug eluting stent (DES) being deployed with a FilterWire EZ in situ (arrows). (E) Distal
balloon to further treat the vessel (arrow). (F) Post-PCI result. ELCA, excimer laser coronary atherectomy; PCI, percutaneous coronary intervention.
TM
Balloon
cases involved an SVG, 13% of the patients presented in cardiogenic shock, and large thrombus burden was present in the
infarct-related vessel (IRA) in 65% of the patients. Adjunctive GPI was administered in 52% of the cases. Following
ELCA, TIMI flow grade was significantly increased from 1.2 to 2.8, along with reduction in angiographic stenosis diameter
from 83% to 52%. Overall a 91% procedural success rate, a 95% device success rate, and a 97% angiographic success rate
were reported [85]. There was a low rate (8.6%) of associated MACEs with a 3% dissection and only 0.6% distal
embolization rate encountered. There were no laser -induced perforations. Mortality of those presenting in cardiogenic
shock was 30%. Importantly, maximal laser effect was observed in lesions laden with a heavy thrombus burden. Separate
analysis of the study’s database demonstrated maximal laser luminal gain among those patients who presented with an
already established Q-wave MI, an ongoing ST-segment elevation, and largeeextensive thrombus burden in the IRA [90].
Further data have suggested that ELCA is capable of removing as much as 80% of the thrombus burden from the treated
targets [91]. The Laser AMI study is the only completed randomized trial of ELCA in acute MI and included just 27
patients. The study demonstrated safety and feasibility but was not powered to determine superiority over conventional
treatments [91]. Two other small registries examining the effects of ELCA in ACS suggested a great er outcome with
regard to TIMI flow and MBG compared with manual thrombus aspiration devices [92,93].
Although ELCA shows promise, its use in clinical practice remains limited, due to a number of factors, which include
limited access to the technology and also prohibitive costs. However, there is scope for this technique to be developed into
a more mainstream technology, though further data are required before adoption into routine clinical practice can be
mandated.

Acute Myocardial Infarction: STEMI and NSTEMI Chapter | 9 141
https://t.me/med1917
(A) (B) (C)
1.4mm ELCA
(D) (E)
Filterwire EZ
FIGURE 9.8 Use of laser in thrombotic occlusion of a vein graft. (A) Occluded vessel (arrow). (B) Thrombus evident following wiring of the graft
(star). (C) Laser catheter in situ (arrow). (D) Reduced thrombus burden on angiogram (star). (E) Stent deployment with FilterWire EZ (arrow) in situ. (F)
Post-PCI result. ELCA, excimer laser coronary atherectomy; PCI, percutaneous coronary intervention.
TM
(F)
CONCLUSIONS
The pathophysiology of ACS and both ST-elevated and non-ST-elevated MI revolves around atherothrombosis with the
presence of intracoronary thrombus often evident on angiographic examination. The methods of treatment of MI and the
consequences of the atherothrombotic cascade are complex and multifaceted, including pharmacotherapies aimed at
treating all components of the platelet and clotting cascade, intending to disrupt and minimize the impact of these on PCI
outcomes and infarct size. Mechanical thrombus extraction during ACS PCI procedures has been increasingly investigated,
with the routine use of thrombectomy devices shown to have only limited impact. Nonetheless, further advances in this
field, which remains an unmet need, may yet yield methods of thrombus disruption to improve PCI outcomes, enacting
change on short- and longer-term clinical outcomes post-MI.
REFERENCES
[1] Hamm CW, Bassand JP, Agewall S, Bax J, Boersma E, Bueno H, Caso P, Dudek D, Gielen S, Huber K, Ohman M, Petrie MC, Sonntag F, Uva MS,
Storey RF, Wijns W, Zahger D, Bax JJ, Auricchio A, Baumgartner H, Ceconi C, Dean V, Deaton C, Fagard R, Funck-Brentano C, Hasdai D,
Hoes A, Knuuti J, Kolh P, McDonagh T, Moulin C, Poldermans D, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Torbicki A, Vahanian A,
Windecker S, Achenbach S, Badimon L, Bertrand M, Botker HE, Collet JP, Crea F, Danchin N, Falk E, Goudevenos J, Gulba D, Hambrecht R,
Herrmann J, Kastrati A, Kjeldsen K, Kristensen SD, Lancellotti P, Mehilli J, Merkely B, Montalescot G, Neumann FJ, Neyses L, Perk J, Roffi M,
Romeo F, Ruda M, Swahn E, Valgimigli M, Vrints CJ, Widimsky P, Guidelines ESCCfP. ESC guidelines for the management of acute coronary
syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the management of acute coronary syndromes (ACS)
in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011;32:2999e3054.

142 Cardiovascular Thrombus
https://t.me/med1917
[2] O’Gara PT, Kushner FG, Ascheim DD, Casey Jr DE, Chung MK, de Lemos JA, Ettinger SM, Fang JC, Fesmire FM, Franklin BA, Granger CB,
Krumholz HM, Linderbaum JA, Morrow DA, Newby LK, Ornato JP, Ou N, Radford MJ, Tamis-Holland JE, Tommaso CL, Tracy CM, Woo YJ,
Zhao DX, Anderson JL, Jacobs AK, Halperin JL, Albert NM, Brindis RG, Creager MA, DeMets D, Guyton RA, Hochman JS, Kovacs RJ,
Kushner FG, Ohman EM, Stevenson WG, Yancy CW, American College of Cardiology Foundation/American Heart Association Task Force on
Practice G. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology
Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013;127:e362e425.
[3] Jneid H, Anderson JL, Wright RS, Adams CD, Bridges CR, Casey Jr DE, Ettinger SM, Fesmire FM, Ganiats TG, Lincoff AM, Peterson ED,
Philippides GJ, Theroux P, Wenger NK, Zidar JP. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable
angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American
College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2012;60:645e81.
[4] Napodano M, Pasquetto G, Sacca S, Cernetti C, Scarabeo V, Pascotto P, Reimers B. Intracoronary thrombectomy improves myocardial reperfusion
in patients undergoing direct angioplasty for acute myocardial infarction. J Am Coll Cardiol 2003;42:1395e402.
[5] Napodano M, Ramondo A, Tarantini G, Peluso D, Compagno S, Fraccaro C, Frigo AC, Razzolini R, Iliceto S. Predictors and time-related impact of
distal embolization during primary angioplasty. Eur Heart J 2009;30:305e13.
[6] van Ommen V, Michels R, Heymen E, van Asseldonk J, Bonnier H, Vainer J, de Swart H, Koolen J. Usefulness of the rescue PT catheter to remove
fresh thrombus from coronary arteries and bypass grafts in acute myocardial infarction. Am J Cardiol 2001;88:306e8.
[7] Rinfret S, Katsiyiannis PT, Ho KK, Cohen DJ, Baim DS, Carrozza JP, Laham RJ. Effectiveness of rheolytic coronary thrombectomy with the
AngioJet catheter. Am J Cardiol 2002;90:470e6.
[8] Burzotta F, Trani C, Romagnoli E, Mazzari MA, Rebuzzi AG, De Vita M, Garramone B, Giannico F, Niccoli G, Biondi-Zoccai GG,
Schiavoni G, Mongiardo R, Crea F. Manual thrombus-a spiration improves myocardial reperfusion: the randomized evaluation of the effect of
mechanical reduction of distal embolization by thrombus-aspiration in primary and rescue angioplasty (REMEDIA) trial. J Am Coll Cardiol
2005;46:371e6.
[9] Dudek D, Mielecki W, Legutko J, Chyrchel M, Sorysz D, Bartus S, Rzeszutko L, Dubiel JS. Percutaneous thrombectomy with the RESCUE system
in acute myocardial infarction. Kardiol Pol 2004;61:523e33.
[10] Silva-Orrego P, Colombo P, Bigi R, Gregori D, Delgado A, Salvade P, Oreglia J, Orrico P, de Biase A, Piccalo G, Bossi I, Klugmann S. Thrombus
aspiration before primary angioplasty improves myocardial reperfusion in acute myocardial infarction: the DEAR-MI (dethrombosis to enhance
acute reperfusion in myocardial infarction) study. J Am Coll Cardiol 2006;48:1552e9.
[11] van ’t Hof AW, Liem A, Suryapranata H, Hoorntje JC, de Boer MJ, Zijlstra F. Angiographic assessment of myocardial reperfusion in patients treated
with primary angioplasty for acute myocardial infarction: myocardial blush grade. Zwolle Myocardial Infarction Study Group. Circulation
1998;97:2302e6.
[12] Xian Y, Wang TY, McCoy LA, Effron MB, Henry TD, Bach RG, Zettler ME, Baker BA, Fonarow GC, Peterson ED. Association of discharge
aspirin dose with outcomes after acute myocardial infarction: insights from the treatment with ADP receptor inhibitors: longitudinal assessment of
treatment patterns and events after acute coronary syndrome (TRANSLATE-ACS) study. Circulation 2015;132:174e81.
[13] Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2.
ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet 1988;2:349e60.
[14] Antithrombotic Trialists C, Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, Buring J, Hennekens C, Kearney P, Meade T,
Patrono C, Roncaglioni MC, Zanchetti A. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of
individual participant data from randomised trials. Lancet 2009;373:1849e60.
[15] Sibbing D, Massberg S. Restoring platelet function in patients on P2Y12 receptor inhibitor treatment: still some issues to be solved! Circ Cardiovasc
Interv 2015;8.
[16] Scavone M, Femia EA, Caroppo V, Cattaneo M. Inhibition of the platelet P2Y12 receptor for adenosine diphosphate does not impair the capacity of
platelet to synthesize thromboxane A2. Eur Heart J 2015;37.
[17] Gent M. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996;348.
[18] Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK, Clopidogrel in Unstable Angina t o Prevent Recurrent Events Trial I.
Effects of clopidogrel in addit ion to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med
2001;345:494e502.
[19] Steinhubl SR, Berger PB, Mann 3rd JT, Fry ET, DeLago A, Wilmer C, Topol EJ, Observation CICftRoED. Early and sustained dual oral antiplatelet
therapy following percutaneous coronary intervention: a randomized controlled trial. J Am Med Assoc 2002;288:2411e20.
[20] Mishkel GJ, Aguirre FV, Ligon RW, Rocha-Singh KJ, Lucore CL. Clopidogrel as adjunctive antiplatelet therapy during coronary stenting. J Am
Coll Cardiol 1999;34:1884e90.
[21] Chen ZM, Jiang LX, Chen YP, Xie JX, Pan HC, Peto R, Collins R, Liu LS, group Cc. Addition of clopidogrel to aspirin in 45,852 patients with
acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005;366:1607e21.
[22] Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J,
Weerakkody G, Gibson CM, Antman EM, Investigators T-T. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med
2007;357:2001e15.
[23] Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM,
Skene A, Steg PG, Storey RF, Harrington RA, Investigators P, Freij A, Thorsen M. Ticagrelor versus clopidogrel in patients with acute coronary
syndromes. N Engl J Med 2009;361:1045e57.

Acute Myocardial Infarction: STEMI and NSTEMI Chapter | 9 143
https://t.me/med1917
[24] Fox KA, Mehta SR, Peters R, Zhao F, Lakkis N, Gersh BJ, Yusuf S, Clopidogrel in Unstable angina to prevent Recurrent ischemic Events T.
Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute
coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) trial. Circulation 2004;110:1202e8.
[25] Jernberg T, Payne CD, Winters KJ, Darstein C, Brandt JT, Jakubowski JA, Naganuma H, Siegbahn A, Wallentin L. Prasugrel achieves greater
inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery
disease. Eur Heart J 2006;27:1166e73.
[26] Wallentin L, Varenhorst C, James S, Erlinge D, Braun OO, Jakubowski JA, Sugidachi A, Winters KJ, Siegbahn A. Prasugrel achieves greater and
faster P2Y12 receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients
with coronary artery disease. Eur Heart J 2008;29:21e30.
[27] Zhang L, Yang J, Zhu X, Wang X, Peng L, Li X, Cheng P, Yin T. Effect of high-dose clopidogrel according to CYP2C19*2 genotype in patients
undergoing percutaneous coronary intervention- a systematic review and meta-analysis. Thromb Res 2015;135:449e58.
[28] Kuliczkowski W, Witkowski A, Polonski L, Watala C, Filipiak K, Budaj A, Golanski J, Sitkiewicz D, Pregowski J, Gorski J, Zembala M,
Opolski G, Huber K, Arnesen H, Kristensen SD, De Caterina R. Interindividual variability in the response to oral antiplatelet drugs: a position paper
of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society,
endorsed by the Working Group on Thrombosis of the European Society of Cardiology. Eur Heart J 2009;30:426e35.
[29] Tantry US, Bonello L, Aradi D, Price MJ, Jeong YH, Angiolillo DJ, Stone GW, Curzen N, Geisler T, Ten Berg J, Kirtane A, Siller-Matula J,
Mahla E, Becker RC, Bhatt DL, Waksman R, Rao SV, Alexopoulos D, Marcucci R, Reny JL, Trenk D, Sibbing D, Gurbel PA, Working Group on
On-Treatment Platelet R. Consensus and update on the de finition of on-treatment platelet reactivity to adenosine diphosphate associated with
ischemia and bleeding. J Am Coll Cardiol 2013;62:2261e73.
[30] von Beckerath N, Taubert D, Pogatsa-Murray G, Schomig E, Kastrati A, Schomig A. Absorption, metabolization, and antiplatelet effects of 300-,
600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (intracoronary stenting and antithrombotic regimen: choose between 3
high oral doses for immediate clopidogrel effect) trial. Circulation 2005;112:2946e50.
[31] Wiviott SD, Antman EM, Winters KJ, Weerakkody G, Murphy SA, Behounek BD, Carney RJ, Lazzam C, McKay RG, McCabe CH, Braunwald E,
Investigators J-T. Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in
percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial. Circulation
2005;111:3366e73.
[32] Nicolau JC, Bhatt DL, Roe MT, Lokhnygina Y, Neely B, Corbalan R, Leiva-Pons JL, Martinez F, Goodman SG, Winters KJ, Verheugt FW,
Armstrong PW, White HD, Fox KA, Prabhakaran D, Ohman EM, Investigators TA. Concomitant proton-pump inhibitor use, platelet activity, and
clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel and managed without revascularization:
insights from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes trial. Am Heart J
2015;170:683e694 e3.
[33] Wilcox R, Iqbal K, Costigan T, Lopez-Sendon J, Ramos Y, Widimsky P. An analysis of TRITON-TIMI 38, based on the 12 month recommended
length of therapy in the European label for prasugrel. Curr Med Res Opin 2014;30:2193e205.
[34] Roe MT, Armstrong PW, Fox KA, White HD, Prabhakaran D, Goodman SG, Cornel JH, Bhatt DL, Clemmensen P, Martinez F, Ardissino D,
Nicolau JC, Boden WE, Gurbel PA, Ruzyllo W, Dalby AJ, McGuire DK, Leiva-Pons JL, Parkhomenko A, Gottlieb S, Topacio GO, Hamm C,
Pavlides G, Goudev AR, Oto A, Tseng CD, Merkely B, Gasparovic V, Corbalan R, Cinteza M, McLendon RC, Winters KJ, Brown EB,
Lokhnygina Y, Aylward PE, Huber K, Hochman JS, Ohman EM, Investigators TA. Prasugrel versus clopidogrel for acute coronary syndromes
without revascularization. N Engl J Med 2012;367:1297e309.
[35] Storey RF, Husted S, Harrington RA, Heptinstall S, Wilcox RG, Peters G, Wickens M, Emanuelsson H, Gurbel P, Grande P, Cannon CP. Inhibition
of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary
syndromes. J Am Coll Cardiol 2007;50:1852e6.
[36] Husted S, Emanuelsson H, Heptinstall S, Sandset PM, Wickens M, Peters G. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible
P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J
2006;27:1038e47.
[37] Mahaffey KW, Wojdyla DM, Carroll K, Becker RC, Storey RF, Angiolillo DJ, Held C, Cannon CP, James S, Pieper KS, Horrow J, Harrington RA,
Wallentin L, Investigators P. Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO)
trial. Circulation 2011;124:544e54.
[38] Thomas MR, Morton AC, Hossain R, Chen B, Luo L, Shahari NN, Hua P, Beniston RG, Judge HM, Storey RF. Morphine delays the onset of action
of prasugrel in patients with prior history of ST-elevation myocardial infarction. Thromb Haemost 2016;116.
[39] Hobl EL, Stimpfl T, Ebner J, Schoergenhofer C, Derhaschnig U, Sunder-Plassmann R, Jilma-Stohlawetz P, Mannhalter C, Posch M, Jilma B.
Morphine decreases clopidogrel concentrations and effects: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol
2014;63:630e5.
[40] Silvain J, Storey RF, Cayla G, Esteve JB, Dillinger JG, Rousseau H, Tsatsaris A, Baradat C, Salhi N, Hamm CW, Lapostolle F, Lassen JF, Collet JP,
Ten Berg JM, Van’t Hof AW, Montalescot G. P2Y12 receptor inhibition and effect of morphine in patients undergoing primary PCI for ST-segment
elevation myocardial infarction. The PRIVATE-ATLANTIC study. Thromb Haemost 2015;116.
[41] Bhatt DL, Stone GW, Mahaffey KW, Gibson CM, Steg PG, Hamm CW, Price MJ, Leonardi S, Gallup D, Bramucci E, Radke PW, Widimsky P,
Tousek F, Tauth J, Spriggs D, McLaurin BT, Angiolillo DJ, Genereux P, Liu T, Prats J, Todd M, Skerjanec S, White HD, Harrington RA, Investigators CP. Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med 2013;368:1303e13.

144 Cardiovascular Thrombus
https://t.me/med1917
[42] Steg PG, Bhatt DL, Hamm CW, Stone GW, Gibson CM, Mahaffey KW, Leonardi S, Liu T, Skerjanec S, Day JR, Iwaoka RS, Stuckey TD,
Gogia HS, Gruberg L, French WJ, White HD, Harrington RA, Investigators C. Effect of cangrelor on periprocedural outcomes in percutaneous
coronary interventions: a pooled analysis of patient-level data. Lancet 2013;382:1981e92.
[43] Angiolillo DJ, Bhatt DL, Steg PG, Stone GW, White HD, Gibson CM, Hamm CW, Price MJ, Prats J, Liu T, Mahaffey KW, Harrington RA. Impact
of cangrelor overdosing on bleeding complications in patients undergoing percutaneous coronary intervention: insights from the CHAMPION trials.
J Thromb Thrombolysis 2015;40:317e22.
[44] Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, Bax JJ, Borger MA, Brotons C, Chew DP, Gencer B, Hasenfuss G,
Kjeldsen K, Lancellotti P, Landmesser U, Mehilli J, Mukherjee D, Storey RF, Windecker S. 2015 ESC guidelines for the management of acute
coronary syndromes in patients presenting without persistent ST-segment elevation. Rev Esp Cardiol 2015;68:1125.
[45] De Luca G, Suryapranata H, Stone GW, Antoniucci D, Tcheng JE, Neumann FJ, Van de Werf F, Antman EM, Topol EJ. Abciximab as adjunctive
therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. J Am Med Assoc
2005;293:1759e65.
[46] Ellis SG, Tendera M, de Belder MA, van Boven AJ, Widimsky P, Janssens L, Andersen HR, Betriu A, Savonitto S, Adamus J, Peruga JZ,
Kosmider M, Katz O, Neunteufl T, Jorgova J, Dorobantu M, Grinfeld L, Armstrong P, Brodie BR, Herrmann HC, Montalescot G, Neumann FJ,
Effron MB, Barnathan ES, Topol EJ, Investigators F. Facilitated PCI in patients with ST-elevation myocardial infarction. N Engl J Med
2008;358:2205e17.
[47] Stone GW, McLaurin BT, Cox DA, Bertrand ME, Lincoff AM, Moses JW, White HD, Pocock SJ, Ware JH, Feit F, Colombo A, Aylward PE,
Cequier AR, Darius H, Desmet W, Ebrahimi R, Hamon M, Rasmussen LH, Rupprecht HJ, Hoekstra J, Mehran R, Ohman EM, Investigators A.
Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006;355:2203e16.
[48] Stone GW, Ware JH, Bertrand ME, Lincoff AM, Moses JW, Ohman EM, White HD, Feit F, Colombo A, McLaurin BT, Cox DA, Manoukian SV,
Fahy M, Clayton TC, Mehran R, Pocock SJ, Investigators A. Antithrombotic strategies in patients with acute coronary syndromes undergoing early
invasive management: one-year results from the ACUITY trial. J Am Med Assoc 2007;298:2497e506.
[49] Kastrati A, Neumann FJ, Schulz S, Massberg S, Byrne RA, Ferenc M, Laugwitz KL, Pache J, Ott I, Hausleiter J, Seyfarth M, Gick M, Antoniucci D,
Schomig A, Berger PB, Mehilli J, Investigators I-RT. Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction. N Engl
J Med 2011;365:1980e9.
[50] O’Donoghue M, Antman EM, Braunwald E, Murphy SA, Steg PG, Finkelstein A, Penny WF, Fridrich V, McCabe CH, Sabatine MS, Wiviott SD.
The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing
percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with
Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis. J Am Coll Cardiol 2009;54:678e85.
[51] Task Force m, Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, Filippatos G, Hamm C, Head SJ, Juni P, Kappetein AP, Kastrati A,
Knuuti J, Landmesser U, Laufer G, Neumann FJ, Richter DJ, Schauerte P, Sousa Uva M, Stefanini GG, Taggart DP, Torracca L, Valgimigli M,
Wijns W, Witkowski A. 2014 ESC/EACTS guidelines on myocardial revascularization: the Task Force on myocardial revascularization of the
European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) developed with the special contribution
of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2014;35:2541e619.
[52] Oler A, Whooley MA, Oler J, Grady D. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable
angina. A meta-analysis. J Am Med Assoc 1996;276:811e5.
[53] Magee KD, Sevcik W, Moher D, Rowe BH. Low molecular weight heparins versus unfractionated heparin for acute coronary syndromes. Cochrane
Database Syst Rev 2003:CD002132.
[54] de Lemos JA, Blazing MA, Wiviott SD, Brady WE, White HD, Fox KA, Palmisano J, Ramsey KE, Bilheimer DW, Lewis EF, Pfeffer M, Califf RM,
Braunwald E, Investigators. Enoxaparin versus unfractionated heparin in patients treated with tirofiban, aspirin and an early conservative initial
management strategy: results from the A phase of the A-to-Z trial. Eur Heart J 2004;25:1688e94.
[55] Fitchett DH, Langer A, Armstrong PW, Tan M, Mendelsohn A, Goodman SG, Investigators ITL-TF-U. Randomized evaluation of the efficacy of
enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein
IIb/IIIa inhibitor eptifibatide. Long-term results of the Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment
(INTERACT) trial. Am Heart J 2006;151:373e9.
[56] Fifth Organization to Assess Strategies in Acute Ischemic Syndromes I, Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J, Granger CB,
Budaj A, Peters RJ, Bassand JP, Wallentin L, Joyner C, Fox KA. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl
J Med 2006;354:1464e76.
[57] Yusuf S, Mehta SR, Chrolavicius S, Afzal R, Pogue J, Granger CB, Budaj A, Peters RJ, Bassand JP, Wallentin L, Joyner C, Fox KA, Group O-T.
Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized
trial. J Am Med Assoc 2006;295:1519e30.
[58] Group FO-T, Steg PG, Jolly SS, Mehta SR, Afzal R, Xavier D, Rupprecht HJ, Lopez-Sendon JL, Budaj A, Diaz R, Avezum A, Widimsky P,
Rao SV, Chrolavicius S, Meeks B, Joyner C, Pogue J, Yusuf S. Low-dose vs standard-dose unfractionated heparin for percutaneous coronary
intervention in acute coronary syndromes treated with fondaparinux: the FUTURA/OASIS-8 randomized trial. J Am Med Assoc
2010;304:1339e49.
[59] Waksman R, Bertrand O, Driesman M, Gruberg L, Rossi J, Mehta S, Swymelar S, Dvir D, Xue Z, Torguson R. Bivalirudin versus unfractionated
heparin during percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndrome initially treated with fon-
daparinux: results from an international, multicenter, randomized pilot study (SWITCH III). J Interv Cardiol 2013;26:107
e13.

Acute Myocardial Infarction: STEMI and NSTEMI Chapter | 9 145
https://t.me/med1917
[60] Chuang YJ, Swanson R, Raja SM, Olson ST. Heparin enhances the specificity of antithrombin for thrombin and factor Xa independent of the
reactive center loop sequence. Evidence for an exosite determinant of factor Xa specificity in heparin-activated antithrombin. J Biol Chem
2001;276:14961e71.
[61] Stone GW, Ohman EM. Antithrombin alternatives in STEMI. Lancet 2011;378:643e5.
[62] Bittl JA, Ahmed WH. Relation between abrupt vessel closure and the anticoagulant response to heparin or bivalirudin during coronary angioplasty.
Am J Cardiol 1998;82:50Pe6P.
[63] Bittl JA, Strony J, Brinker JA, Ahmed WH, Meckel CR, Chaitman BR, Maraganore J, Deutsch E, Adelman B. Treatment with bivalirudin (Hirulog)
as compared with heparin during coronary angioplasty for unstable or postinfarction angina. Hirulog Angioplasty Study Investigators. N Engl J Med
1995;333:764e9.
[64] Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Dangas G, Wong SC,
Kirtane AJ, Parise H, Mehran R, Investigators H-AT. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med
2008;358:2218e30.
[65] Tobbia P, Brodie BR, Witzenbichler B, Metzger C, Guagliumi G, Yu J, Kellett MA, Stuckey T, Fahy M, Mehran R, Stone GW. Adverse event rates
following primary PCI for STEMI at US and non-US hospitals: three-year analysis from the HORIZONS-AMI trial. EuroIntervention
2013;8:1134e42.
[66] Shahzad A, Kemp I, Mars C, Wilson K, R oome C, Cooper R, Andron M, Appleby C, Fisher M, Khand A, Kunadian B, Mills JD, Morris JL,
Morrison WL, Munir S, Palmer ND, Perry RA, Ramsdale DR, Velavan P, Stables RH, investigators H-Pt. Unfractionated heparin versus
bivalirudin in primary percutaneous coronary i ntervention (HEAT-PPCI): an open-label, single centre, randomised controll ed trial. Lancet
2014;384:1849e58.
[67] Steg PG, van ’t Hof A, Hamm CW, Clemmensen P, Lapostolle F, Coste P, Ten Berg J, Van Grunsven P, Eggink GJ, Nibbe L, Zeymer U, Campo
dell’ Orto M, Nef H, Steinmetz J, Soulat L, Huber K, Deliargyris EN, Bernstein D, Schuette D, Prats J, Clayton T, Pocock S, Hamon M, Goldstein P,
Investigators E. Bivalirudin started during emergency transport for primary PCI. N Engl J Med 2013;369:2207e17.
[68] Han Y, Guo J, Zheng Y, Zang H, Su X, Wang Y, Chen S, Jiang T, Yang P, Chen J, Jiang D, Jing Q, Liang Z, Liu H, Zhao X, Li J, Li Y, Xu B,
Stone GW, Investigators B. Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial
infarction: the BRIGHT randomized clinical trial. J Am Med Assoc 2015;313:1336e46.
[69] Valgimigli M, Frigoli E, Leonardi S, Rothenbuhler M, Gagnor A, Calabro P, Garducci S, Rubartelli P, Briguori C, Ando G, Repetto A, Limbruno U,
Garbo R, Sganzerla P, Russo F, Lupi A, Cortese B, Ausiello A, Ierna S, Esposito G, Presbitero P, Santarelli A, Sardella G, Varbella F, Tresoldi S, de
Cesare N, Rigattieri S, Zingarelli A, Tosi P, van ’t Hof A, Boccuzzi G, Omerovic E, Sabate M, Heg D, Juni P, Vranckx P, Investigators M.
Bivalirudin or unfractionated heparin in acute coronary syndromes. N Engl J Med 2015;373:997e1009.
[70] Alexander JH, Lopes RD, James S, Kilaru R, He Y, Mohan P, Bhatt DL, Goodman S, Verheugt FW, Flather M, Huber K, Liaw D, Husted SE,
Lopez-Sendon J, De Caterina R, Jansky P, Darius H, Vinereanu D, Cornel JH, Cools F, Atar D, Leiva-Pons JL, Keltai M, Ogawa H, Pais P,
Parkhomenko A, Ruzyllo W, Diaz R, White H, Ruda M, Geraldes M, Lawrence J, Harrington RA, Wallentin L, Investigators A. Apixaban with
antiplatelet therapy after acute coronary syndrome. N Engl J Med 2011;365:699e708.
[71] Oldgren J, Budaj A, Granger CB, Khder Y, Roberts J, Siegbahn A, Tijssen JG, Van de Werf F, Wallentin L, Investigators R-D. Dabigatran vs.
placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. Eur Heart J
2011;32:2781e9.
[72] Tricoci P, Huang Z, Held C, Moliterno DJ, Armstrong PW, Van de Werf F, White HD, Aylward PE, Wallentin L, Chen E, Lokhnygina Y, Pei J,
Leonardi S, Rorick TL, Kilian AM, Jennings LH, Ambrosio G, Bode C, Cequier A, Cornel JH, Diaz R, Erkan A, Huber K, Hudson MP, Jiang L,
Jukema JW, Lewis BS, Lincoff AM, Montalescot G, Nicolau JC, Ogawa H, Pfisterer M, Prieto JC, Ruzyllo W, Sinnaeve PR, Storey RF,
Valgimigli M, Whellan DJ, Widimsky P, Strony J, Harrington RA, Mahaffey KW, Investigators T. Thrombin-receptor antagonist vorapaxar in acute
coronary syndromes. N Engl J Med 2012;366:20e33.
[73] Sianos G, Papafaklis MI, Daemen J, Vaina S, van Mieghem CA, van Domburg RT, Michalis LK, Serruys PW. Angiographic stent thrombosis after
routine use of drug-eluting stents in ST-segment elevation myocardial infarction: the importance of thrombus burden. J Am Coll Cardiol
2007;50:573e83.
[74] Burzotta F, Trani C, Romagnoli E, Belloni F, Biondi-Zoccai GG, Mazzari MA, De Vita M, Giannico F, Garramone B, Niccoli G, Rebuzzi AG,
Mongiardo R, Schiavoni G, Crea F. A pilot study with a new, rapid-exchange, thrombus-aspirating device in patients with thrombus-containing
lesions: the Diver C.E. study. Catheter Cardiovasc Interv 2006;67(6):887e93.
[75] Svilaas T, Vlaar PJ, van der Horst IC, Diercks GFH, de Smet BJGL, van den Heuvel Ad FM, Anthonio RL, Jessurun GA, Tan E, Suurmeijer AJH,
Zijlstra F. Thrombus aspiration during primary percutaneous coronary intervention. NEJM 2008;358:557e67.
[76] Vlaar PJ, Svilaas T, van der Horst IC, Diercks GF, Fokkema ML, de Smet BJ, van den Heuvel AF, Anthonio RL, Jessurun GA, Tan ES,
Suurmeijer AJ, Zijlstra F. Cardiac death and reinfarction after 1 year in the Thrombus Aspiration during Percutaneous coronary intervention in Acute
myocardial infarction Study (TAPAS): a 1-year follow-up study. Lancet 2008;371:1915e20.
[77] Kaltoft A, Bøttcher M, Nielsen SS, Hansen HH, Terkelsen C, Maeng M, Kristensen J, Thuesen L, Krusell LR, Kristensen SD, Andersen HR,
Lassen JF, Rasmussen K, Rehling M, Nielsen TT, Bøtker HE. Routine thrombectomy in percutaneous coronary intervention for acute ST-segment-
elevation myocardial infarction: a randomized, controlled trial. Circulation 2006;114:40e7.
[78] Stone GW, Maehara A, Witzenbichler B, Godlewski J, Parise H, Dambrink JH, Ochala A, Carlton TW, Cristea E, Wolff SD, Brener SJ,
Chowdhary S, El-Omar M, Neunteufl T, Metzger DC, Karwoski T, Dizon JM, Mehran R, Gibson CM, INFUSE-AMI Investigators. Intracoronary
abciximab and aspiration thrombectomy in patients with large anterior myocardial infarction: the INFUSE-AMI randomized trial. J Am Med Assoc
2012;307:1817e26.

146 Cardiovascular Thrombus
https://t.me/med1917
[79] Fröbert O, Lagerqvist B, Olivecrona GK, Omerovic E, Gudnason T, Maeng M, Aasa M, Angerås O, Calais F, Danielewicz M, Erlinge D, Hellsten L,
Jensen U, Johansson AC, Kåregren A, Nilsson J, Robertson L, Sandhall L, Sjögren I, Ostlund O, Harnek J, James SK, TASTE Trial. Thrombus
aspiration during ST-segment elevation myocardial infarction. NEJM 2013;369:1587e97.
[80] De Luca G, Navarese EP, Suryapranata H. A meta-analytic overview of thrombectomy during primary angioplasty. Int J Cardiol
2013;166(3):606e12.
[81] Elgendy IY, Huo T, Bhatt DL, Bavry AA. Is aspiration thrombectomy Beneficial in patients Undergoing primary percutaneous coronary inter-
vention? Circ Cardiovasc Interv 2015;8(7):1e8.
[82] Jolly SS, Cairns JA, Yusuf S, Meeks B, Pogue J, Rokoss MJ, Kedev S, Thabane L, Stankovic G, Moreno R, Gershlick A, Chowdhary S, Lavi S,
Niemelä K, Steg PG, Bernat I, Xu Y, Cantor WJ, Overgaard CB, Naber CK, Cheema AN, Welsh RC, Bertrand OF, Avezum A, Bhindi R,
Pancholy S, Rao SV, Natarajan MK, ten Berg JM, Shestakovska O, Gao P, Widimsky P, Dzavík V, TOTAL Investigators. Randomized trial of
primary PCI with or without routine manual thrombectomy. NEJM 2015;372:1389e98.
[83] Topaz O, Rozenbaum EA, Luxenberg MG, Schumacher A. Laser-assisted coronary angioplasty in patients with severely depressed left ventricular
function: quantitative coronary angiography and clinical results. J Interv Cardiol 1995;8:661e9.
[84] Topaz O, Minisi AJ, Bernardo N, Alimar R, Ereso A, Shah R. Comparison of effectiveness of excimer laser angioplasty in patients with acute
coronary syndromes in those with versus those without normal left ventricular function. Am J Cardiol 2003;91:797e802.
[85] Topaz O, Ebersole D, Das T, Alderman EL, Madyoon H, Vora K, Baker JD, Hilton D, Dahm JB, trial Cm. Excimer laser angioplasty in acute
myocardial infarction (the CARMEL multicenter trial). Am J Cardiol 2004;93:694e701.
[86] Dahm JB, Topaz O, Woenckhaus C, Staudt A, Mox B, Hummel A, Felix SB. Laser-facilitated thrombectomy: a new therapeutic option for treatment
of thrombus-laden coronary lesions. Catheter Cardiovasc Interv 2002;56:365e72.
[87] Topaz O, Minisi AJ, Morris C, Mohanty PK, Carr Jr ME. Photoacoustic fibrinolysis: pulsed-wave, mid-infrared laser-clot interaction. J Thromb
Thrombolysis 1996;3:209e14.
[88] Topaz O, Minisi AJ, Bernardo NL, McPherson RA, Martin E, Carr SL, Carr Jr ME. Alterations of platelet aggregation kinetics with ultraviolet laser
emission: the “stunned platelet” phenomenon. Thromb Haemost 2001;86:1087e93.
[89] Topaz O, Bernardo NL, Shah R, McQueen RH, Desai P, Janin Y, Lansky AJ, Carr ME. Effectiveness of excimer laser coronary angioplasty in acute
myocardial infarction or in unstable angina pectoris. Am J Cardiol 2001;87:849e55.
[90] Group CELIS, Topaz O, Ebersole D, Dahm JB, Alderman EL, Madyoon H, Vora K, Baker JD, Hilton D, Das T. Excimer laser in myocardial
infarction: a comparison between STEMI patients with established Q-wave versus patients with non-STEMI (non-Q). Lasers Med Sci
2008;23:1e10.
[91] Dorr M, Vogelgesang D, Hummel A, Staudt A, Robinson DM, Felix SB, Dahm JB. Excimer laser thrombus elimination for prevention of distal
embolization and no-reflow in patients with acute ST elevation myocardial infarction: results from the randomized LaserAMI study. Int J Cardiol
2007;116:20e6.
[92] Niccoli G, Belloni F, Cosentino N, Fracassi F, Falcioni E, Roberto M, Panico RA, Mongiardo R, Porto I, Leone AM, Burzotta F, Trani C, Crea F.
Case-control registry of excimer laser coronary angioplasty versus distal protection devices in patients with acute coronary syndromes due to
saphenous vein graft disease. Am J Cardiol 2013;112:1586e91.
[93] Shishikura D, Otsuji S, Takiuchi S, Fukumoto A, Asano K, Ikushima M, Yasuda T, Hasegawa K, Kashiyama T, Yabuki M, Hanafusa T,
Higashino Y. Vaporizing thrombus with excimer laser before coronary stenting improves myocardial reperfusion in acute coronary syndrome. Circ J
2013;77:1445e52.

Chapter 10
https://t.me/med1917
Acute Coronary Syndrome: Thrombotic
Lesions in Patients With Unstable Angina
Gabriele Cioni1, Nayef A. Abouzaki2and Ion S. Jovin
1
University of Florence, Florence, Italy;2Virginia Commonwealth University and McGuire Veterans’ Administration Medical Center, Richmond, VA,
United States
2
UNSTABLE ANGINA
Definition
An acute coronary syndrome (ACS) is a constellation of signs and symptoms associated with insuf ficient flow through the
coronary tree and the resultant acute ischemia of the myocardium. The cardinal sign of a patient with ACS is chest pain that
is usually described as central, substernal, like a pressure, and it can be nonradiating or can radiate to the left shoulder, to
the jaw, or to the left arm. The chest pain or chest discomfort can be accompanied by shortness of breath, diaphoresis,
and sometimes an impending sense of doom. The term ACS usual ly encompasses three different subtypes of clinical
presentations, unstable angina, non-ST (-segment) elevation myocardial infarction (NSTEMI), and ST (-segment) elevation
myocardial infarction (STEMI) [1], that are considered to be mostly various manifestations of the same problem (coronary
atherosclerosis and thrombosis with disruption of flow in the coronary artery and ischemia in the subtended myocardium).
However, the same presentations can be caused by coronary spasm, coronary thromboembolism, high inotropic states, and
low oxygen states [2], but these occur much less frequently than coronary occlusion due to thrombus formation.
The distinction between NSTEMI and STEMI is based on the clinical presentation with chest pain, the presence of
positive cardiac biomarkers, and the presence or absence of ST-segment elevations on the electrocardiogram (ECG).
Unstable angina is a purely clinical diagnosis in a patient with chest pain, without positive cardiac biomarkers, and without
ST-segment elevation on ECG. The patient may have other ECG changes such as ST-segment depressions and/or T-wave
changes, which support the diagnosis, but ultimately the diagnosis of unstable angina is a clinical diagnosis based primarily
on history and physical examination. While unstable angina is most commonly chest pain at rest, new-onset exertional
angina in the previous 2 months and exertional angina of increasing frequency at the same or lower level of exertion are
also grouped with unstable angina. These classifications are based on clinical observations in the past that certain patterns
of angina were heralds of more serious events such as myocardial infarction and death. For these reasons, what we call
unstable angina used to be called preinfarction angina or crescendo angina [3]. With the advent of increasingly sensitive
cardiac biomarker tests, we have recognized that most people presenting with chest pain who have high pretest probability
for myocardial injury have some degree of positive enzym es, and thus the incidence of NSTEMI has increased while the
incidence of unstable angina has decreased [4,5] (Fig. 10 .1). This chapter will focus on unstable angina caused by a
thrombus at the site of a ruptured unstable plaque or by erosion of a plaque. The thrombus causes partial or intermittently
complete obstruction of flow and ischemia that is pronounced enough to cause symptoms but not prolonged enough to
cause myocardial necrosis and abnormal biomarkers.
Epidemiology
Cardiovascular disease is the single most frequent cause of morbidity and mortality among people in Western countries and
is rapidly becoming the leading cause of death [6,7] around the world. In the United States every year nearly 1.2 million
Cardiovascular Thrombus. https://doi.org/10.1016/B978-0-12-812615-8.00010-7
Copyright © 2018 Elsevier Inc. All rights reserved.
147

148 Cardiovascular Thrombus
https://t.me/med1917
FIGURE 10.1 Chest pain and acute coronary syndrome. The flow of patients and the progression of diagnosis. NSTEMI, non-ST-segment elevation
myocardial infarction; STEMI, ST-segment elevation myocardial infarction.
patients are hospitalized for ACS, even as the proportion of ACS with STEMI seems to be declining [8,9]. In the 2016
Heart Disease and Stroke Statistics update of the American Heart Association it was reported that more than 15 million
people in the United States have coronary artery disease [10]. The prevalence of coronary artery disease increases with age
for both women and men and it has been estimated that an Ameri can suffers a myocardial infarction every 42 s. The
incidence and prevalence of unstable angina are much more difficult to determine because unstable angina is a diagnosis of
exclusion. However, it is noteworthy that chest pain is one of the leading causes of adult emergency room visits the United
States [11].
Data from the Framingham Study showed that women trailed behind men in incidence of myocardial infarction and
sudden death by 20 years, but the sex ratio gap decreased with advancing age [12]. Myocardial infarction or sudden death
was infrequent in premenopausal women and the burden of coronary artery disease was markedly higher among postmenopausal women compared with their premenopausal age-matched referents [13,14]. Data from 360,000 residents ages
35e74 years in four communities in the Atherosclerosis Risk in Communities study showed that the age-adjusted incidence of hospitalized myoca rdial infarction was highest among black men and lowest among white women [15].
PATHOLOGY AND PATHOPHYSIOLOGY OF THE THROMBOTIC LESION
Thrombosis
The onset and progression of atherosclerotic disease involve the deposition of extracellular lipids into the intimal layer of
the arterial wall and the activation and proliferation of proinflammatory markers, bone-marrow-derived cells, and local
smooth muscle cells [16]. The progression of an atherosclerotic plaque is often asymptomatic for years and becomes
clinically apparent only because of a thrombotic complication. Hemostasis is a complex network of cellular and humoral
systems, involving the platelet system, the coagulation process, the anticoagulant, and the fibrinolytic pathways; these
systems are the main actors of equilibrium between antithrombotic and prothrombotic factors [17,18].
Several studies identified platelets as the link between different systemic pathways, exerting a key role in the formation
of the atheromatous lesion and in the clinical onset of acute atherothrombotic events. In particular, the exposure of the
subendothelial matrix of the eroded plaque is the trigger for platelet adhesion, activation, and aggregation [19,20].
According to several studies, platelet adhesion to the endothelium amplifies inflammatory response; in particular, the
recruitment of inflammatory cells, such as monocytes, stimulates production of several adhesion molecules (P-selectin,
intercellular adhesion molecule-1) and chemokines (monocyte chemoattractant protein-1, interleukin [IL]-1b, IL-8, cluster
of differentiation 40 ligand [CD40L], regulated on activation, normal T cell expressed and secreted [RANTES]) and
induces platelet conformational changes. Secretion of agonists, especially thromboxane A
cellular phospholipase A
binding and final formation of plateletemonocyte aggregates [21].
, stimulates the platelet intra-
2
ephosphokinase C pathway, with subsequent glycoprotein IIb/IIIa expression and fibrinogen
2

Acute Coronary Syndrome: Thrombotic Lesions in Patients With Unstable Angina Chapter | 10 149
https://t.me/med1917
Different studies demonstrated that platelets are the major contributors to microcirculatory dysfunction and vascular
inflammation, while hyperactivity was observed in the unstable disease state. Platelet hyperreactivity or local platelet
activation in acute coronary events were described by Trip et al. [22]. Persistent platelet activation in ACS patients on dual
antiplatelet treatment was associated with an increased thrombin generation and a high risk for ischemic events and subacute stent thrombosis [23e25]. The formation of monocyteeplatelet aggregates induces a procoagulant state; in this
scenario, von Willebrand factor represents the link between the hemostatic and the inflammatory system, providing an
adhesive component for monocytes and neutrophils [26]. Lipoprotein-associated phospholipase A
(Lp-PLA2) is considered
2
to exert properties at the crossroads between lipid metabolism and the inflammatory response; the localization of Lp-PLA
in atherosclerotic lesions was described, and several studies suggested a causal role for Lp-PLA2in plaque instability [27].
Biomechanical forces have an important role in coronary atherosclerotic plaque development, progression, and rupture.
The stre ss related to the biomechanical forces affecting coronary arteries during each cardiac cycle was able to alter both
wall shear stress and plaque structural stress, stimulating the expression of inflammatory molecules and modifying
endothelial function. The plaque structural stress affects the inner body of atherosclerotic lesions, and it is determined not
only by pulsatile injury on the vessel wall, but also by composition and morphology of the plaque tissues [28].
Therefore, the different characteristics of the atherosclerotic lesions could alter the plaque stress and modify endothelial
homeostasis, leading to an increase in the structural stress and precipitating the rupture of the plaque [29e31].
Inflammation
The role of cytokine-driven inflammation and tissue destruction is becoming recognized as a major determinant of
atherosclerotic lesion progression and instability. A disturbed flow at atherosclerosis-prone sites can alter the homeostasis
of endothelial cells and their molecular synthesis and proliferation [32e34]. In particular, this imbalance may induce
cellular apoptosis, activating pathways of c-Jun N-terminal kinase 1 (JNK1), cellular tumor antigen p53 (p53), and protein
kinase C-z; moreover, endothelial proliferation may be affected by the downregulation of microRNA species and the
induction of irreversible cell senescence via the p53ep21 pathway [35e37]. These data are supported by the detection of
an increased inflammatory burden at sites exposed to altered flow and predisposed to the progression of atherosclerotic
lesions [38].
Endothelial activation stimulates the production of several inflammatory mediators, including several cytokines, such as
tumor necrosis factor a and IL-1, and oxidized lipoproteins; furthermore, biomechanical wall stress may contribute to this
proinflammatory burden, altering the activity of several pathways, such as nuclear factor kB (NF-kB) and mitogenactivated protein (MAP) kinase signaling. The induction of inflammatory genes by NF-kB, secondary to the associated
JNKecAMP-dependent transcription factor ATF2 pathway, induces the overexpression of the NFKB3 and NFKB1
proteins, and primes endothelial cells for activation in response to other circulating markers of cardiovascular damage, such
as hypercholesterolemia [39]. Conversely, the MAP kinase JNK and p38 pathway induces a proinflammatory response,
involving the downstream acti vator protein 1 family of transcription factors.
The expression of matrix metalloproteinases (MMPs) is involved in inflammation and vascular remodeling and promotes atherosclerosis; moreover, monocyte adhesion is stimulated by the expression of inflammatory adhesion molecules,
such as Junctional Adhesion Molecule A (also known as F11R). Activation of metalloproteinases and monocyte migration
leads to plaque growth and instability.
An excessive expansive remodeling may alter vascular structure and morphology, leading to an increase in both lumen
and vessel dimensions and to rapid plaque progression [40]. Studies have reported contradictory findings regarding the
association between turbulent flow and arterial remodeling, showing that both constrictive remodeling and eccentric plaque
development were observed in regions with low wall stress [41] .
Evidence suggests that angiogenesis could play a key role in the transformation into a vulnerable plaque. In particular,
angiogenesis is linked to an inflammatory pattern and it depends on the combined actions of different cytokines and growth
factors produced by infiltrating inflammatory cells. Activated T lymphocytes, which were observed in areas of neoangiogenesis within the deep intima media and around the necrotic core, are a known source of angiogenic factors, such as
vascular endo thelial growth factor, and may play an important role in the development of intraplaque vasa vasorum [42].
Barger et al. demonstrated a rich network of vasa vasorum within human atherosclerotic coronary vessels [43]. Moreover,
vasa vasorum correlated with intimal macrophage content and was higher in individuals with previous cardiovascular
events [44]. Angiogenic factors, derived from T lymphocytes and macrophages, stimulate neovascularization, contributing
to the growth of vasa vasorum and immature vessels around the necrotic core. The rapid accumulation of erythrocyte
membranes could alter the plaque structure by an increase in free cholesterol within the necrotic core, further stimulating
macrophage infiltration and contributing to necrotic core enlargement.
2
Соседние файлы в папке Библиотека им академика М.И. Перельмана
